Sera Prognostics, Inc. Class A Common Stock (SERA) is a publicly traded Healthcare sector company. As of May 21, 2026, SERA trades at $1.82 with a market cap of $68.53M and a P/E ratio of -2.69. SERA moved +2.30% today. Year to date, SERA is -42.48%; over the trailing twelve months it is -16.98%. Its 52-week range spans $1.37 to $9.13. Analyst consensus is buy with an average price target of $0.00. Rallies surfaces SERA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PreTRM Trial Cuts Early Preterm Births 56%, Sera Extends Cash Runway to 2029: Sera Prognostics reported Q1 revenue of $14,000 (vs. $38,000), with expenses of $9.4 million and R&D spend of $3.0 million. Landmark PRIME trial showed PreTRM cut early preterm births by 56% (<32 weeks), NICU admissions by 20% and morbidity by 20%, and the company extended its cash runway to 2029.
| Metric | Value |
|---|---|
| Price | $1.82 |
| Market Cap | $68.53M |
| P/E Ratio | -2.69 |
| EPS | $-0.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.13 |
| 52-Week Low | $1.37 |
| Volume | 148 |
| Avg Volume | 0 |
| Revenue (TTM) | $57.00K |
| Net Income | $-32.14M |
| Gross Margin | -191.23% |
2 analysts cover SERA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $0.00.